<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188421</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-018125</org_study_id>
    <secondary_id>NA_00037871</secondary_id>
    <secondary_id>R01DA018125</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT01188421</nct_id>
  </id_info>
  <brief_title>Medications Development for Drug Abuse Disorders</brief_title>
  <official_title>Medications Development for Drug Abuse Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of tramadol as an agent for short-term opioid withdrawal treatment. A
      randomized, double blind clinical trial comparing the efficacy and safety of tramadol to
      clonidine and buprenorphine in the short-term treatment of opioid withdrawal will be
      conducted. Opioid dependent participants will be treated on a residential unit. The primary
      outcome measure is opioid withdrawal symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Ratings on Clinical Opiate Withdrawal Scale (COWS) Measure of Withdrawal During Double-blind Taper (7-days) and Post-taper (7-days) Period.</measure>
    <time_frame>14 days total</time_frame>
    <description>Outcomes represent mean peak withdrawal as rated on the Clinical Opiate Withdrawal Scale (COWS) total score. Withdrawal was collected 7 times daily and daily peak values were identified for each participant and averaged together as a function of group. Primary outcomes were mean peak results from the 7-day taper period and first 7 days post-taper. The COWS is an 11-item observer-rated measure of opioid withdrawal severity. Items are rated on individual Likert scales and the total score range is 0-47. Higher values indicate more severe withdrawal.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Opioid Related Disorders</condition>
  <condition>Opioid Dependence</condition>
  <condition>Opioid Addiction</condition>
  <arm_group>
    <arm_group_label>buprenorphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sublingual buprenorphine/naloxone tablets (or placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clonidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral clonidine tablets (or placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tramadol ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tramadol tablets (or placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/naloxone</intervention_name>
    <description>up to 8/2 mg Sublingual (SL) per day</description>
    <arm_group_label>buprenorphine</arm_group_label>
    <other_name>Suboxone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>up to 0.8 mg per day (oral)</description>
    <arm_group_label>clonidine</arm_group_label>
    <other_name>Catapres</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol ER</intervention_name>
    <description>up to 600 mg per day</description>
    <arm_group_label>tramadol ER</arm_group_label>
    <other_name>Ultram</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion/Exclusion Criteria:

          -  Participants in this study will be males and females between the ages of 18 and 60
             years.

          -  Applicants must be opioid dependent based upon the Structured Clinical Interview for
             Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (SCID); in addition,
             they must have an opioid positive urine during the screening process (or have evidence
             of opioid withdrawal).

          -  They must be healthy, with no significant medical illnesses (e.g., insulin dependent
             diabetes), and without significant psychiatric illness (e.g., schizophrenia) besides
             their drug dependence.

          -  Females will have a pregnancy test prior to study enrollment, and if found to be
             pregnant will be excluded and referred to a substance abuse program for pregnant women
             (the Center for Addiction and Pregnancy) on the campus.

          -  Volunteers will also be excluded if they have pre-admission hypotension (due to the
             use of clonidine in the study).

          -  Applicants with a history of seizures (including substance-related seizures, such as
             alcohol withdrawal related) will be excluded.

          -  Alcohol and/or sedative dependence will be specific exclusionary criteria (given the
             small risk of seizures associated with tramadol use).

          -  Allergies to any of the study medications will be grounds for exclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric C. Strain, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University (BPRU) Bayview Campus</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2010</study_first_submitted>
  <study_first_submitted_qc>August 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2010</study_first_posted>
  <results_first_submitted>April 17, 2017</results_first_submitted>
  <results_first_submitted_qc>June 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 6, 2017</results_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Buprenorphine</title>
          <description>Sublingual buprenorphine/naloxone tablets (or placebo)
Buprenorphine/naloxone: up to 8/2 mg SL per day</description>
        </group>
        <group group_id="P2">
          <title>Tramadol ER</title>
          <description>Oral tramadol tablets (or placebo)
Tramadol ER: up to 600 mg per day</description>
        </group>
        <group group_id="P3">
          <title>Clonidine</title>
          <description>Oral clonidine tablets (or placebo)
Clonidine: up to 0.8 mg per day (oral)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Buprenorphine</title>
          <description>Sublingual buprenorphine/naloxone tablets (or placebo)
Buprenorphine/naloxone: up to 8/2 mg SL per day</description>
        </group>
        <group group_id="B2">
          <title>Tramadol ER</title>
          <description>Oral tramadol tablets (or placebo)
Tramadol ER: up to 600 mg per day</description>
        </group>
        <group group_id="B3">
          <title>Clonidine</title>
          <description>Oral clonidine tablets (or placebo)
Clonidine: up to 0.8 mg per day (oral)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="10.9"/>
                    <measurement group_id="B2" value="40.9" spread="9.7"/>
                    <measurement group_id="B3" value="41.5" spread="10.5"/>
                    <measurement group_id="B4" value="41.2" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.7"/>
                    <measurement group_id="B2" value="47.2"/>
                    <measurement group_id="B3" value="41.6"/>
                    <measurement group_id="B4" value="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Ratings on Clinical Opiate Withdrawal Scale (COWS) Measure of Withdrawal During Double-blind Taper (7-days) and Post-taper (7-days) Period.</title>
        <description>Outcomes represent mean peak withdrawal as rated on the Clinical Opiate Withdrawal Scale (COWS) total score. Withdrawal was collected 7 times daily and daily peak values were identified for each participant and averaged together as a function of group. Primary outcomes were mean peak results from the 7-day taper period and first 7 days post-taper. The COWS is an 11-item observer-rated measure of opioid withdrawal severity. Items are rated on individual Likert scales and the total score range is 0-47. Higher values indicate more severe withdrawal.</description>
        <time_frame>14 days total</time_frame>
        <population>Repeated measures ANOVA</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Sublingual buprenorphine/naloxone tablets (or placebo)
Buprenorphine/naloxone: up to 8/2 mg SL per day</description>
          </group>
          <group group_id="O2">
            <title>Tramadol ER</title>
            <description>Oral tramadol tablets (or placebo)
Tramadol ER: up to 600 mg per day</description>
          </group>
          <group group_id="O3">
            <title>Clonidine</title>
            <description>Oral clonidine tablets (or placebo)
Clonidine: up to 0.8 mg per day (oral)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Ratings on Clinical Opiate Withdrawal Scale (COWS) Measure of Withdrawal During Double-blind Taper (7-days) and Post-taper (7-days) Period.</title>
          <description>Outcomes represent mean peak withdrawal as rated on the Clinical Opiate Withdrawal Scale (COWS) total score. Withdrawal was collected 7 times daily and daily peak values were identified for each participant and averaged together as a function of group. Primary outcomes were mean peak results from the 7-day taper period and first 7 days post-taper. The COWS is an 11-item observer-rated measure of opioid withdrawal severity. Items are rated on individual Likert scales and the total score range is 0-47. Higher values indicate more severe withdrawal.</description>
          <population>Repeated measures ANOVA</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Taper Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.79" spread="1.68"/>
                    <measurement group_id="O2" value="8.41" spread="0.70"/>
                    <measurement group_id="O3" value="8.28" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taper Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.16" spread="2.03"/>
                    <measurement group_id="O2" value="6.10" spread="0.72"/>
                    <measurement group_id="O3" value="8.00" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taper Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.76" spread="1.77"/>
                    <measurement group_id="O2" value="3.77" spread="0.35"/>
                    <measurement group_id="O3" value="5.85" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taper Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" spread="1.77"/>
                    <measurement group_id="O2" value="4.25" spread="0.52"/>
                    <measurement group_id="O3" value="4.70" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taper Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31" spread="2.11"/>
                    <measurement group_id="O2" value="3.25" spread="0.37"/>
                    <measurement group_id="O3" value="3.32" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taper Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="1.63"/>
                    <measurement group_id="O2" value="3.39" spread="0.45"/>
                    <measurement group_id="O3" value="3.57" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taper Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="1.28"/>
                    <measurement group_id="O2" value="3.69" spread="0.53"/>
                    <measurement group_id="O3" value="3.86" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Taper Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.82" spread="1.62"/>
                    <measurement group_id="O2" value="3.36" spread="0.44"/>
                    <measurement group_id="O3" value="3.27" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Taper Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.62" spread="1.90"/>
                    <measurement group_id="O2" value="4.48" spread="0.60"/>
                    <measurement group_id="O3" value="4.09" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Taper Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.23" spread="1.75"/>
                    <measurement group_id="O2" value="3.28" spread="0.28"/>
                    <measurement group_id="O3" value="3.68" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Taper Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.49" spread="1.66"/>
                    <measurement group_id="O2" value="3.13" spread="0.24"/>
                    <measurement group_id="O3" value="3.82" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Taper Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.87" spread="1.69"/>
                    <measurement group_id="O2" value="2.75" spread="0.24"/>
                    <measurement group_id="O3" value="3.27" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Taper Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.91" spread="1.62"/>
                    <measurement group_id="O2" value="2.57" spread="0.26"/>
                    <measurement group_id="O3" value="2.91" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Taper Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.91" spread="1.69"/>
                    <measurement group_id="O2" value="2.30" spread="0.23"/>
                    <measurement group_id="O3" value="2.41" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A power analysis determined 40 participants in each group would detect a moderate effect size, assuming an alpha of 0.05 and 80% power. Due to the expiration of buprenorphine tablets, recruitment was terminated after enrolling 103 participants. This study utilized an Intent-to-Treat (ITT) analysis. The ITT analysis includes all volunteers who signed informed consent, were randomized into the study's treatment conditions, and took at least 1 dose of study medication.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.275</p_value>
            <p_value_desc>Main effect of Group (e.g., Buprenorphine, Tramadol, Clonidine) on COWS Total Score Ratings</p_value_desc>
            <method>ANOVA</method>
            <param_type>F-value for main effect of Group</param_type>
            <param_value>1.310</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>Main effect for Phase (e.g., Stabilization, Taper, Post-Taper) on COWS total score.</p_value_desc>
            <method>ANOVA</method>
            <param_type>F-value for main effect of Phase</param_type>
            <param_value>3.570</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.092</p_value>
            <p_value_desc>Main effect for Group x Phase interaction on COWS Total Score</p_value_desc>
            <method>ANOVA</method>
            <param_type>F-value for the main effect of Group x P</param_type>
            <param_value>2.030</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are reported from the Taper and Post-Taper periods (approximately 18-19 days). No Adverse Events reported from Stabilization phase (7-10 day period) since this occurred prior to primary experimental manipulation and randomization to study drug (clonidine, tramadol, buprenorphine).</time_frame>
      <desc>Standard terminology</desc>
      <group_list>
        <group group_id="E1">
          <title>Buprenorphine</title>
          <description>Sublingual buprenorphine/naloxone tablets (or placebo)
Buprenorphine/naloxone: up to 8/2 mg SL per day</description>
        </group>
        <group group_id="E2">
          <title>Tramadol ER</title>
          <description>Oral tramadol tablets (or placebo)
Tramadol ER: up to 600 mg per day</description>
        </group>
        <group group_id="E3">
          <title>Clonidine</title>
          <description>Oral clonidine tablets (or placebo)
Clonidine: up to 0.8 mg per day (oral)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>High heart rate</description>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Cramp</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="31"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E3" events="25" subjects_affected="20" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Flatulance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="36"/>
                <counts group_id="E3" events="21" subjects_affected="17" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="31"/>
                <counts group_id="E2" events="22" subjects_affected="14" subjects_at_risk="36"/>
                <counts group_id="E3" events="19" subjects_affected="10" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <description>stupor or coma from disease</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>uneasiness or indisposition</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>non-productive</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="31"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E3" events="16" subjects_affected="10" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Yawning</sub_title>
                <description>Excessively</description>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Piloerection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Sweat Increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>pain in joint</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cramp Lower Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Muscle Ache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="31"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="36"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain Lower Extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E3" events="10" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="31"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="36"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="31"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="36"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Shaky</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eric C. Strain, MD</name_or_title>
      <organization>Johns Hopkins University, School of Medicine</organization>
      <phone>410-550-1191</phone>
      <email>estrain1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

